Mohammed Qureshi
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1821408188
Payments from drug & device makers
Across 317 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$808
- Corcept Therapeutics$490
- Lilly USA, LLC$383
- AstraZeneca$346
- Cequr Corporation$331
- plus $3K from 33 others
What the payments were for
- Travel & lodging$75010%
- Food & beverage$6,43689%
- Education$260%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $1,616 |
| Amgen(2 entities) | 33 | $808 |
| Corcept Therapeutics | 17 | $490 |
| Lilly USA, LLC | 20 | $383 |
| AstraZeneca(2 entities) | 21 | $346 |
| Cequr Corporation | 2 | $331 |
| Abbott | 15 | $323 |
| Radius Health, Inc. | 24 | $282 |
| Dexcom, Inc. | 10 | $278 |
| Boehringer Ingelheim | 16 | $263 |
| Companion Medical, Inc. | 4 | $195 |
| Sanofi-aventis U.S. LLC | 9 | $174 |
| Bayer | 10 | $157 |
| Esperion Therapeutics, Inc. | 9 | $156 |
| Recordati_rare_diseases_inc. | 6 | $138 |
| IBSA Pharma Inc. | 9 | $130 |
| Mannkind Corporation | 5 | $123 |
| Insulet Corporation | 6 | $106 |
| Veloxis Pharmaceuticals, Inc. | 3 | $102 |
| Zealand Pharma US, Inc. | 5 | $88 |
| Amryt Pharma Holdings Ltd | 5 | $87 |
| Antares Pharma, Inc. | 5 | $80 |
| Tandem Diabetes Care, Inc. | 4 | $80 |
| Intuity Medical Inc | 4 | $79 |
| EUSA Pharma (US) LLC | 3 | $77 |
| Amneal Pharmaceuticals LLC | 3 | $56 |
| Nevro Corp. | 2 | $53 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| Calliditas Therapeutics US Inc. | 2 | $35 |
| AbbVie | 2 | $32 |
| Astellas Pharma US Inc | 2 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| BETA Bionics, Inc. | 1 | $17 |
| Merck | 1 | $13 |
| Vivus LLC | 1 | $13 |
| Pfizer | 1 | $13 |
| Johnson & Johnson | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$331
- Prolia$116
- Korlym$111
- InPen$107
- FreeStyle Libre 2$106
How this compares
$7,271 in reported general payments places this provider in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $180,247 |
| JardianceEmpagliflozin | 72 | $70,592 |
| MounjaroTirzepatide | 49 | $58,167 |
| TrulicityDulaglutide | 37 | $50,928 |
| RybelsusSemaglutide | 15 | $27,447 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 33 | $26,952 |
| FarxigaDapagliflozin Propanediol | 21 | $20,649 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $13,127 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $9,818 |
| TradjentaLinagliptin | 12 | $8,616 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $5,584 |
| Novolog FlexpenInsulin Aspart | 22 | $4,543 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,583 |
| SynthroidLevothyroxine Sodium | 17 | $1,143 |
| Alendronate Sodium | 58 | $1,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,616 | $207,694159 claims |
| Lilly USA, LLCMounjaro, Trulicity | $383 | $109,09586 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $263 | $106,161117 claims |
| AstraZenecaFarxiga | $346 | $20,64921 claims |
| AbbVieSynthroid | $32 | $1,14317 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $56 | $865107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Maria CabanillasHouston$16.4M
- Damaris VegaHouston$12.3M
- Amer Al KaradshehHouston$8.8M
- Amir HassanHouston$5.2M
- Camilo JimenezHouston$5M
- Rocio HarbisonHouston$3.2M
- Gerardo BuesoHouston$1.2M
- Veena WatweHouston$976K
- Andres SplenserHouston$923K
- Prashant KoshyHouston$795K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.